McNeel DG - Search Results

1

Targeted Radiation and Immune Therapies-Advances and Opportunities for the Treatment of Prostate Cancer.

Muralidhar A, Potluri HK, Jaiswal T, McNeel DG. Muralidhar A, et al. Among authors: mcneel dg. Pharmaceutics. 2023 Jan 11;15(1):252. doi: 10.3390/pharmaceutics15010252. Pharmaceutics. 2023. PMID: 36678880 Free PMC article. Review.

2

Immunization with recombinant human granulocyte-macrophage colony-stimulating factor as a vaccine adjuvant elicits both a cellular and humoral response to recombinant human granulocyte-macrophage colony-stimulating factor.

McNeel DG, Schiffman K, Disis ML. McNeel DG, et al. Blood. 1999 Apr 15;93(8):2653-9. Blood. 1999. PMID: 10194445 Free article. Clinical Trial.

3

Clinical translation of peptide-based vaccine trials: the HER-2/neu model.

Disis ML, Knutson KL, McNeel DG, Davis D, Schiffman K. Disis ML, et al. Among authors: mcneel dg. Crit Rev Immunol. 2001;21(1-3):263-73. Crit Rev Immunol. 2001. PMID: 11642608 Review.

4

An aberrant prostate antigen-specific immune response causes prostatitis in mice and is associated with chronic prostatitis in humans.

Hou Y, DeVoss J, Dao V, Kwek S, Simko JP, McNeel DG, Anderson MS, Fong L. Hou Y, et al. Among authors: mcneel dg. J Clin Invest. 2009 Jul;119(7):2031-41. doi: 10.1172/JCI38332. J Clin Invest. 2009. PMID: 19603556 Free PMC article.

5

Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patients with prostate cancer.

McNeel DG, Nguyen LD, Ellis WJ, Higano CS, Lange PH, Disis ML. McNeel DG, et al. Prostate. 2001 May 15;47(3):222-9. doi: 10.1002/pros.1066. Prostate. 2001. PMID: 11351352

6

Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization.

Disis ML, Schiffman K, Gooley TA, McNeel DG, Rinn K, Knutson KL. Disis ML, et al. Among authors: mcneel dg. Clin Cancer Res. 2000 Apr;6(4):1347-50. Clin Cancer Res. 2000. PMID: 10778962

7

His-tag ELISA for the detection of humoral tumor-specific immunity.

Goodell V, McNeel D, Disis ML. Goodell V, et al. BMC Immunol. 2008 May 29;9:23. doi: 10.1186/1471-2172-9-23. BMC Immunol. 2008. PMID: 18510754 Free PMC article.

8

Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen.

Dubovsky JA, McNeel DG, Powers JJ, Gordon J, Sotomayor EM, Pinilla-Ibarz JA. Dubovsky JA, et al. Among authors: mcneel dg. Clin Cancer Res. 2009 May 15;15(10):3406-15. doi: 10.1158/1078-0432.CCR-08-2099. Epub 2009 Apr 28. Clin Cancer Res. 2009. PMID: 19401350

9

Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.

Fong L, Kwek SS, O'Brien S, Kavanagh B, McNeel DG, Weinberg V, Lin AM, Rosenberg J, Ryan CJ, Rini BI, Small EJ. Fong L, et al. Among authors: mcneel dg. Cancer Res. 2009 Jan 15;69(2):609-15. doi: 10.1158/0008-5472.CAN-08-3529. Cancer Res. 2009. PMID: 19147575 Clinical Trial.

10

Identification of T helper epitopes from prostatic acid phosphatase.

McNeel DG, Nguyen LD, Disis ML. McNeel DG, et al. Cancer Res. 2001 Jul 1;61(13):5161-7. Cancer Res. 2001. PMID: 11431355

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

141 results

Search Page

Filters